USFDA issues inspection report for Vizag facility
NATCO Pharma Limited has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Finished Dosage Formulations (FDF) manufacturing facility at Parawada, Visakhapatnam, Andhra Pradesh.
According to the company's regulatory disclosure dated November 20, 2026, the USFDA conducted an inspection at the facility between August 17 and August 21, 2026. At the conclusion of the inspection, the company received four observations recorded in Form 483.
The company has now confirmed that the USFDA issued the EIR, classifying the inspection as Voluntary Action Indicated (VAI).
What does VAI classification mean?
A VAI classification indicates that the regulator identified conditions requiring attention, but the findings do not currently warrant official regulatory action. The company is expected to address the observations through appropriate voluntary corrective measures.
The classification is distinct from an inspection outcome in which no action is indicated. It should not be interpreted as meaning that all four observations have been eliminated or that the facility has received an unconditional clearance.
Company disclosure
NATCO Pharma announced the development through a press release issued on November 20 under its regulatory disclosure obligations. The announcement follows the company's earlier communication dated August 21 regarding the inspection observations.
Headquartered in Hyderabad, NATCO Pharma develops and manufactures generic and branded medicines, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company serves more than 50 global markets.
The EIR provides an update on the regulatory outcome of the August inspection at the Visakhapatnam formulations facility.
Team Hello Vizag